Sandostatin LAR
What it is used for
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: – Carcinoid tumours with features of the carcinoid syndrome; – Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
How to take it
This medicine is a pack that contains more than one part.
Part 1: Diluent, not applicable
Clear, colourless to slightly brown solution injection kit 3 ml glass syringe, stainless steel safety needle and vial adapter in a rigid plastic tray.
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
Part 2: Injection, modified release
White to white with yellowish tint powder in glass vial sealed with rubber stopper and aluminium fliptop seal.
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
How to take it
This medicine is a pack that contains more than one part.
Part 1: Diluent, not applicable
Clear, colourless to slightly brown solution injection kit 3 ml glass syringe, stainless steel safety needle and vial adapter in a rigid plastic tray.
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
Part 2: Injection, modified release
White to white with yellowish tint powder in glass vial sealed with rubber stopper and aluminium fliptop seal.
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Pregnant or planning a pregnancy?
For the active ingredient octreotide
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.